http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H06234643-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_afd115dec46c157d3739020ebd4d866b |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57 |
| filingDate | 1993-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_676c857c56204c3aacf5f859b9ed7c9f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d24fe646104385f7f85fb53bcf3cff4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_779b211ce7a9b75c74233f3fa9628b8f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af1b1990a8171711caa8bf793791e247 |
| publicationDate | 1994-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-H06234643-A |
| titleOfInvention | Topical steroid |
| abstract | (57) [Summary] [Structure] A fatty acid-derived ester bond having 12 to 22 carbon atoms at the 21st position and an aliphatic carboxylic acid having 2 to 5 carbon atoms at the 17th position (however, when the antiinflammatory steroid is dexamethasone, An anti-inflammatory external preparation containing a steroid compound having an ester bond derived from a fatty acid having 2 to 5 carbon atoms or an alicyclic carboxylic acid having 5 carbon atoms. [Effect] When administered to an affected area of inflammation, the steroid ester body is percutaneously absorbed and then specifically concentrated on the site of inflammation, and the ester bond is cleaved according to the degree of inflammation, and the steroid has a medicinal effect. The surplus steroid ester form moves into the blood as it is and is excreted by detoxification and metabolism. When transdermally administered to the non-inflammatory part, it is excreted as an inactive ester form via the same route as the surplus. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-100439388-C |
| priorityDate | 1993-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 59.